Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus SER A GEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus SER A GEN.
ALDORIL 25 vs SER-A-GEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
500 mg orally once daily.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination